-=Corbus Pharma (CRBP) : data from Phase 2 lenabasum studies at EULAR 2018

Corbus Pharma announces presentation of 1-year systemic sclerosis and 6-month dermatomyositis data from open-label extension of Phase 2 lenabasum studies at EULAR 2018 

• Multiple key efficacy outcomes were further improved in open-label extensions of systemic sclerosis (SSc) and dermatomyositis (DM) Phase 2 studies.
• Lenabasum continues to demonstrate a favorable safety profile with chronic dosing.
• SSc and DM are related, rare, and serious systemic autoimmune diseases with limited treatment options. There are 120,000 individuals with diffuse cutaneous SSc and DM in US, EU, and Japan.
• 77% of subjects achieved a degree of improvement in mRSS that is considered medically meaningful (reduction greater than or equal to 5 points), and 50% achieved greater than or equal to 10 points improvement in mRSS.
• 88% of DME subjects achieved reduction greater than or equal to 5 points, which is considered medically meaningful, 82% achieved reduction greater than or equal to 10 points, and 47% had reached a low CDASI activity score (less than or equal to 14 points).